{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:08:28Z","timestamp":1761491308123,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011873","name":"Multiple Sclerosis Scientific Research Foundation","doi-asserted-by":"publisher","award":["EGID3185"],"award-info":[{"award-number":["EGID3185"]}],"id":[{"id":"10.13039\/100011873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00415-021-10881-3","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T17:02:27Z","timestamp":1636131747000},"page":"1758-1763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience"],"prefix":"10.1007","volume":"269","clinical-trial-number":[{"clinical-trial-number":"nct03679468","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0132-0909","authenticated-orcid":false,"given":"Anthony","family":"Feinstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Brichetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Chataway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy D.","family":"Chiaravalloti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrik","family":"Dalgas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Feys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Meza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Motl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Assunta","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Sandroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Salter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the CogEx Research Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"10881_CR1","unstructured":"COVID-19 Map\u2014Johns Hopkins Coronavirus Resource Center. [cited 2021 Sep 17]. https:\/\/coronavirus.jhu.edu\/map.html"},{"key":"10881_CR2","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1007\/s00415-020-10045-9","volume":"267","author":"FJ Mateen","year":"2020","unstructured":"Mateen FJ, Rezaei S, Alakel N, Gazdag B, Kumar AR, Vogel A (2020) Impact of COVID-19 on US and Canadian neurologists\u2019 therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices. J Neurol 267:3467\u20133475. https:\/\/doi.org\/10.1007\/s00415-020-10045-9","journal-title":"J Neurol"},{"key":"10881_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/1352458521100533910.1177\/13524585211005339","author":"E Portaccio","year":"2021","unstructured":"Portaccio E, Fonderico M, Hemmer B, Derfuss T, Stankoff B, Selmaj K et al (2021) Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Mult Scler J. https:\/\/doi.org\/10.1177\/1352458521100533910.1177\/13524585211005339","journal-title":"Mult Scler J"},{"issue":"10","key":"10881_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1177\/1352458520948231","volume":"26","author":"BP Moss","year":"2020","unstructured":"Moss BP, Mahajan KR, Bermel RA, Hellisz K, Hua LH, Hudec T et al (2020) Multiple sclerosis management during the COVID-19 pandemic. Mult Scler J 26(10):1163\u20131171","journal-title":"Mult Scler J"},{"key":"10881_CR5","doi-asserted-by":"crossref","unstructured":"Maguire R, Hynes S, Seebacher B, Block VJ, Zackowski KM, Jonsdottir J, et al (2021) Research interrupted: the impact of the COVID-19 pandemic on multiple sclerosis research in the field of rehabilitation and quality of life. Mult Scler J Exp Transl Clin 7(3):205521732110380. https:\/\/us.sagepub.com\/en-us\/nam\/open-access-at-sage","DOI":"10.1177\/20552173211038030"},{"key":"10881_CR6","doi-asserted-by":"crossref","unstructured":"DeLuca J, Chiaravalloti ND, Sandroff BM (2020) Treatment and management of cognitive dysfunction in patients with multiple sclerosis. Nat Rev Neurol 16(6):319\u201332. https:\/\/pubmed.ncbi.nlm.nih.gov\/32372033\/","DOI":"10.1038\/s41582-020-0355-1"},{"key":"10881_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01772-7","author":"A Feinstein","year":"2020","unstructured":"Feinstein A, Amato MP, Brichetto G, Chataway J, Chiaravalloti N, Dalgas U et al (2020) Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). BMC Neurol. https:\/\/doi.org\/10.1186\/s12883-020-01772-7","journal-title":"BMC Neurol"},{"issue":"1","key":"10881_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-021-05245-1","volume":"22","author":"R Lowe","year":"2021","unstructured":"Lowe R, Barlow C, Lloyd B, Latchem-Hastings J, Poile V, Scoble C et al (2021) Lifestyle, Exercise and Activity Package for People living with Progressive Multiple Sclerosis (LEAP-MS): adaptions during the COVID-19 pandemic and remote delivery for improved efficiency. Trials 22(1):1\u20138. https:\/\/doi.org\/10.1186\/s13063-021-05245-1","journal-title":"Trials"},{"key":"10881_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001067","author":"MS Weber","year":"2021","unstructured":"Weber MS, Nicholas JA, Yeaman MR (2021) Balancing potential benefits and risks of bruton tyrosine kinase inhibitor therapies in multiple sclerosis During the COVID-19 pandemic. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001067","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10881_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s43441-020-00160-0","volume":"54","author":"JR Turner","year":"2020","unstructured":"Turner JR (2020) New FDA guidance on general clinical trial conduct in the era of COVID-19 releasing guidances in final form key messages in the guidance on conduct of clinical trials of medical products during the COVID-19 pandemic. Ther Innov Regul Sci 54:723\u2013724. https:\/\/doi.org\/10.1007\/s43441-020-00160-0","journal-title":"Ther Innov Regul Sci"},{"key":"10881_CR11","unstructured":"Healthcare workers: information on COVID-19|CDC. [cited 2021 Sep 17]. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/index.html"},{"key":"10881_CR12","doi-asserted-by":"crossref","unstructured":"Feinstein A, Freeman J, Lo AC. Progressive multiple sclerosis 2 Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. www.thelancet.com\/neurology. 2015 [cited 2021 Jul 27]; www.thelancet.com\/neurology","DOI":"10.1016\/S1474-4422(14)70231-5"},{"issue":"11","key":"10881_CR13","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1177\/1352458512458169","volume":"18","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Thompson A, Baker D, Brown D, Browne P, Chandraratna D et al (2012) Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS New Perspectives. Mult Scler J 18(11):1534\u20131540","journal-title":"Mult Scler J"},{"issue":"7","key":"10881_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1177\/135245852199997010.1177\/1352458521999970","volume":"27","author":"KM Zackowski","year":"2021","unstructured":"Zackowski KM, Freeman J, Brichetto G, Centonze D, Dalgas U, DeLuca J et al (2021) Prioritizing progressive MS rehabilitation research: a call from the International Progressive MS Alliance. Mult Scler J 27(7):989\u20131001. https:\/\/doi.org\/10.1177\/135245852199997010.1177\/1352458521999970","journal-title":"Mult Scler J"},{"key":"10881_CR15","unstructured":"Kennedy RF. Day of affirmation address, University of Capetown, Capetown, South Africa, June 6, 1966 | JFK Library. Papers of Robert F. Kennedy. Senate Papers. Speeches and Press Releases, Box 2, \u201c\u2018Freedom & Democracy\u2019 University of Cape Town, Cape Town, South Africa.\u201d John F. Kennedy Presidential Library. 1966 [cited 2021 Sep 17]. https:\/\/www.jfklibrary.org\/learn\/about-jfk\/the-kennedy-family\/robert-f-kennedy\/robert-f-kennedy-speeches\/day-of-affirmation-address-university-of-capetown-capetown-south-africa-june-6-1966"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10881-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10881-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10881-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T16:17:33Z","timestamp":1647965853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10881-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10881"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10881-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"assertion":[{"value":"22 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anthony Feinstein is on Advisory Boards for Akili Interactive and Roche, and reports grants from the MS Society of Canada, book royalties from Johns Hopkins University Press, Cambridge University Press, Amadeus Press and Glitterati Editions, and speaker\u2019s honoraria from Novartis, Biogen, Roche and Sanofi Genzyme. Maria Pia Amato received compensation for consulting services and\/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Roche, Pharmaceutical Industries and Fondazione Italiana Sclerosi Multiplav. Giampaolo Brichetto has been awarded and receives research support from Roche, Fondazione Italiana Sclerosi Multipla, ARSEP, H2020 EU Call. Jeremy Chataway has received support from the Efficacy and Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership and the Health Technology Assessment (HTA) Programme (NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part by the National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK. He has been a local principal investigator for commercial trials funded by: Actelion, Biogen, Novartis and Roche; has received an investigator grant from Novartis; and has taken part in advisory boards\/consultancy for Azadyne, Biogen, Celgene, MedDay, Merck and Roche. Nancy D. Chiaravalloti is on an Advisory Board for Akili Interactive and is a member of the Editorial Boards of Multiple Sclerosis Journal and Frontiers in NeuroTrauma. Ulrik Dalgas has received research support, travel grants, and\/or teaching honorary from Biogen Idec, Merck-Serono, Novartis, Bayer Schering, and Sanofi Aventis as well as honoraria from serving on scientific advisory boards of Biogen Idec and Genzyme. John DeLuca is an Associate Editor of the Archives of Physical Medicine and Rehabilitation, and Neuropsychology Review; received compensation for consulting services and\/or speaking activities from Biogen Idec, Celgene, MedRhythms, and Novartis; and receives research support from Biogen Idec, National Multiple Sclerosis Society, Consortium of Multiple Sclerosis Centers, and National Institutes of Health. Cecilia Meza has no disclosures to report. Peter Feys is editorial board member of NNR and MSJ, provides consultancy to NeuroCompass and was board of advisory board meetings for BIOGEN. Massimo Filippi is Editor-in-Chief of the Journal of Neurology and Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology, received compensation for consulting services and\/or speaking activities from Alexion, Almirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries, and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, the Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). Jennifer Freeman has been awarded research grants from the NIHR, UK. Matilde Inglese is Co-Editor for Controversies for Multiple Sclerosis Journal; received compensation for consulting services and\/or speaking activities from Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme; and received research support from NIH, NMSS, the MS Society of Canada, the Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, H2020 EU Call. Robert W. Motl has no disclosures to report. Maria Assunta Rocca received speaker honoraria from Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck-Serono, Novartis, Roche, and Teva and research support from the Canadian MS Society and Fondazione Italiana Sclerosi Multipla. Brian Sandroff has no disclosures to report. Gary Cutter is a member of Data and Safety Monitoring Boards for Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb\/Celgene, CSL Behring, Galmed Pharmaceuticals, Horizon Pharmaceuticals,Hisun Pharmaceuticals, Mapi Pharmaceuticals LTD, Merck, Merck\/Pfizer, Opko Biologics, OncoImmune, Neurim, Novartis, Ophazyme, Sanofi Aventis, Reata Pharmaceuticals, Teva pharmaceuticals, VielaBio Inc, Vivus, NHLBI (Protocol Review Committee), NICHD (OPRU oversight committee). He is on Consulting or Advisory Boards for Biodelivery Sciences International, Biogen, Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Klein-Buendel Incorporated, Medimmune, Medday, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion\/Cerexis Pharmaceuticals, Roche, TG Therapeutics. Dr. Cutter is employed by the University of Alabama at Birmingham and President of Pythagoras, Inc. a private consulting company located in Birmingham AL. Amber Salter is a statistical editor for Circulation: Cardiovascular Imaging.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}